Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy-Reference-Cited by-同舟云学术

Validity and usefulness of a single-item measure of patient-reported bother from side effects of cancer therapy

Published:2017-11-13 Issue:5 Volume:124 Page:991-997
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Pearman Timothy P.¹²³^ORCID,Beaumont Jennifer L.¹,Mroczek Daniel¹,O’Connor Mary¹,Cella David¹²⁴

Affiliation:

1. Department of Medical Social Sciences; Northwestern University Feinberg School of Medicine; Chicago Illinois

2. Department of Psychiatry and Behavioral Sciences; Northwestern University Feinberg School of Medicine; Chicago Illinois

3. Supportive Oncology, Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago Illinois

4. Prevention and Control Research, Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Chicago Illinois

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31133/fullpdf

Reference20 articles.

1. Cancer treatment and survivorship statistics, 2016;Miller;CA Cancer J Clin,2016

2. Cancer treatment and survivorship statistics, 2014;DeSantis;CA Cancer J Clin,2014

3. Implementation of distress screening in an oncology setting;Pearman;J Community Support Oncol,2015

4. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer;Pike;Chemotherapy Res Pract.,2012

5. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial;Cella;Br J Cancer,2013

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

2. Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial;Nature Medicine;2024-09-14

3. Assessing Side-Effect Bother, Burden, and Tolerability: A Qualitative Study Exploring the Content Validity of the Functional Assessment of Cancer Therapy – Item GP5;2024-08-26

4. Remote Symptom Alerts and Patient-Reported Outcomes (PROS) in Real-World Breast Cancer Practice: Innovative Data to Derive Symptom Burden and Quality of Life;Bioengineering;2024-08-19

5. Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16);Journal of Patient-Reported Outcomes;2024-08-15